Shares of TechTarget, Inc. (NASDAQ:TTGT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

TG Therapeutics is focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. Its portfolio includes azercabtagene zapreleucel (azer-cel), an allogenic CD19 CAR-T ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...